Intepirdine provides new hope for Alzheimer’s disease

Marwan Sabbagh, MD, from Barrow Neurological Institute, Phoenix, AZ provides an overview of his study on the difference in cognitive decline between combination therapy with donepezil and intepirdine (RVT-101) and donepezil monotherapy. Intepirdine is a 5-HT6 selective antagonist which enhances the release of acetylcholine. The results from the Phase IIb study has been very encouraging for intepirdine at 24 weeks and 48 weeks follow up. This interview was recorded at the Alzheimer’s Association International Conference (AAIC) 2017, London, UK.

Share this video